Sotrovimab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Sotrovimab Usage And Synthesis

Uses

Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease[1][2].

in vivo

References

[1] Gupta A, et al; COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021 Nov 18;385(21):1941-1950. DOI:10.1056/NEJMoa2107934
[2] Case JB, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun. 2022 Jul 2;13(1):3824. DOI:10.1038/s41467-022-31615-7
[3] Cathcart A L, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2[J]. biorxiv, 2022: 2021.03. 09.434607.
[4] Aweda TA, et al. In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys. Eur J Nucl Med Mol Imaging. 2022 Oct 28:1–12. DOI:10.1007/s00259-022-06012-3

Sotrovimab(2423014-07-5)Related Product Information

• Brodalumab
• Muromonab-CD3
• Emapalumab
• Figitumumab
• ZanoliMuMab
• Utomilumab
• Afasevikumab
• Intetumumab
• Emactuzumab
• Caplacizumab